Coya Therapeutics, Inc.

COYA

US22407B1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
6.5 ^USD	+8.88%		+7.26%	-12.28%

01/07	Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell Microcap Value Index	CI
01/07	Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell 3000E Value Index	CI

Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell Microcap Value Index

July 01, 2024

Latest news about Coya Therapeutics, Inc.

Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell Microcap Value Index	01/07	CI
Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell 3000E Value Index	01/07	CI
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease	22/05	CI
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	20/05	MT
Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation	20/05	CI
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	17/05	CI
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating	20/03	MT
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03	CI
Coya Therapeutics Expands Intellectual Property Beyond COYA 302 Product Candidate	13/02	MT
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells in Inflammatory Diseases	13/02	CI
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson?s Disease in Addition to Amyotrophic Lateral Sclerosis	16/01	CI
Coya Therapeutics Expects to File COYA 302 IND Application for ALS in Q2 After 'Successful' FDA Meeting; Shares Rise	05/01	MT
Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis	05/01	CI
Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding	12/12	CI
Wilbur Ross Joins Coya Therapeutics' Board	07/12	CI
Coya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drug	06/12	DJ
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories SA Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302	06/12	CI
Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding	05/12	CI
Coya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Coya Therapeutics Completes Enrollment for Phase 2 Study of Low-Dose Interleukin-2 to Treat Alzheimer's Disease	09/23/09	MT
Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer?s Disease (AD)	09/23/09	CI
Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis	05/23/05	CI
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis at the 22nd Annual Northeast ALS Consortium Meeting	03/23/03	CI

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Coya Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.5 USD

Average target price

14.83 USD

Spread / Average Target

+128.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COYA THERAPEUTICS, INC.	-12.28%	98.94M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research